Skip to main content
Heloisa P. Soares
( out of 161 reviews )

Heloisa P. Soares, MD, PhD

Languages spoken: Portuguese, Spanish, English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital South

Clinic 3A, Gastrointestinal
1950 Circle of Hope
Salt Lake City , UT 84112

Dr. Heloisa Soares is a medical oncologist with a focus in neuroendocrine cancers. She is an Associate Professor at the Huntsman Cancer Institute (HCI) at University of Utah. Dr. Soares received her medical degree at Faculdade de Medicine do ABC in Brazil, where she was born. She completed her residency training at the Mount Sinai Medical Center of Florida and her hematology-oncology fellowship training and PhD in molecular biology at UCLA. Dr. Soares has neuroendocrine cancer as the major focus of her research and clinical activities. She serves as the Medical Director for the Clinical Trials Office as well as the co-physician leader in the GI and the Theranostics Clinical Trials Research Groups at HCI . From 2019 to 2024, she served at the board of directors for The North American Neuroendocrine Tumor Society (NANETS). Additionally, she is the co-chair for the NCI NET Taskforce and member of SWOG and NRG cooperative groups. She is also a panel member for the Neuroendocrine and Adrenal Tumors NCCN Clinical Practice Guidelines in Oncology.

At the University of Utah, she leads the University of Utah NET Destination Care Program. At the Huntsman Cancer Institute, she is the Neuroendocrine Tumor Clinical Program and Research Initiative director.

Dr. Soares is a passionate advocate to patients and is a Healing NET Foundation's Board Member. Along many patient-centered activities, she volunteers at the ASCO Advocacy Summit on Capital Hill.

You can follow her on twitter as @helops79

Board Certification

Educational Commission for Foreign Medical Graduates
American Board of Internal Medicine (Sub: Medical Oncology)

Patient Rating

4.9 /5
( out of 161 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

The scale on which responses are measured is 1 to 5 with 5 being the best score.

Patient Comments

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

HUNTSMAN CANCER CENTER

Dr. Soares is in a class by herself. Incredible expertise and personal concern for her patients.

HUNTSMAN CANCER CENTER

Although surprised at residual from gall bladder surgery and lack of full recovery from symptoms, Dr. Soares's assurance of flow up with the GI doctor gave me hope I may improve in the future. Dr. Soares IS the light.

HUNTSMAN CANCER CENTER

Dr. Soares is excellent, both in terms of her subject knowledge and her ability to communicate on a very human level with the patient.

HUNTSMAN CANCER CENTER

Dr. Soares shows concern my health beyond my immediate health issue

HUNTSMAN CANCER CENTER

She went through things very quickly but obviously knows her stuff and was very professional

HUNTSMAN CANCER CENTER

DR Soares is the most awesome doctor there is. Her care is over the top. Thank you. :-))

HUNTSMAN CANCER CENTER

She is an amazing caring doctor and is expert with NETs and puts me at ease I love her

HUNTSMAN CANCER CENTER

Thank you for directing my treatment. It is has been quite a journey and I would not be experiencing the well being I have today without your care.

HUNTSMAN CANCER CENTER

Dr, Soares is the expert I needed to find the correct treatment for my rare cancer. Her knowledge and experience in the field give her the nuances to diagnosis correctly and chose the most appropriate and effective treatment.

Dr. Heloisa Soares is a medical oncologist with a focus in neuroendocrine cancers. She is an Associate Professor at the Huntsman Cancer Institute (HCI) at University of Utah. Dr. Soares received her medical degree at Faculdade de Medicine do ABC in Brazil, where she was born. She completed her residency training at the Mount Sinai Medical Center of Florida and her hematology-oncology fellowship training and PhD in molecular biology at UCLA. Dr. Soares has neuroendocrine cancer as the major focus of her research and clinical activities. She serves as the Medical Director for the Clinical Trials Office as well as the co-physician leader in the GI and the Theranostics Clinical Trials Research Groups at HCI . From 2019 to 2024, she served at the board of directors for The North American Neuroendocrine Tumor Society (NANETS). Additionally, she is the co-chair for the NCI NET Taskforce and member of SWOG and NRG cooperative groups. She is also a panel member for the Neuroendocrine and Adrenal Tumors NCCN Clinical Practice Guidelines in Oncology.

At the University of Utah, she leads the University of Utah NET Destination Care Program. At the Huntsman Cancer Institute, she is the Neuroendocrine Tumor Clinical Program and Research Initiative director.

Dr. Soares is a passionate advocate to patients and is a Healing NET Foundation's Board Member. Along many patient-centered activities, she volunteers at the ASCO Advocacy Summit on Capital Hill.

You can follow her on twitter as @helops79

Board Certification and Academic Information

Academic Departments Internal Medicine -Associate Professor (Clinical)
Radiology & Imaging Sciences -Adjunct Associate Professor
Academic Divisions Oncology
Board Certification
Educational Commission for Foreign Medical Graduates
American Board of Internal Medicine (Sub: Medical Oncology)

Selected Publications

Journal Article

  1. Megale Costa LJ, Soares HP, Gaspar HA, Trujillo LG, Santi PX, Pereira RS, de Santana TL, Pinto FN, del Giglio A (2004). Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol, 27(3), 304-6.
  2. Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G, Clarke M, Bennett CL (2008). Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med, 168(6), 632-42.
  3. Pereira LP, Waisberg J, André EA, Zanoto A, Mendes Júnior JP, Soares HP (2001). Detection of Helicobacter pylori in gastric cancer. Arq Gastroenterol, 38(4), 240-6.
  4. Cives M, Soares HP, Strosberg J (2016). Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Curr Opin Oncol, 28(4), 359-66.
  5. Weinschenker P, Soares HP, Clark O, Del Giglio A (2004). Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis. Breast Cancer Res Treat, 87(3), 215-24.
  6. Manhani AR, Manhani R, Soares HP, Bendit I, Lopes F, Nicoletti AG, Fonseca FL, Novaes M, Zatta SM, Arias V, Giralt S, del Giglio A (2001). CK-19 expression by RT-PCR in the peripheral blood of breast cancer patients correlates with response to chemotherapy. Breast Cancer Res Treat, 66(3), 249-54.
  7. Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A, Reaman G, Chalmers I, Djulbegovic B, Children's Oncology Group. (2005). Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. BMJ, 331(7528), 1295.
  8. Soares HP, Daniels S, Kumar A, Clarke M, Scott C, Swann S, Djulbegovic B, Radiation Therapy Oncology Group. (2004). Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ, 328(7430), 22-4.
  9. Wainberg ZA, Soares HP, Patel R, DiCarlo B, Park DJ, Liem A, Wang HJ, Yonemoto L, Martinez D, Laux I, Brennan M, Hecht JR (2015). Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers. Cancer Chemother Pharmacol, 76(1), 61-7.
  10. Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, Mayo C, Green MR, Silva O, Levi J, Walker G, Rocha-Lima CM (2014). A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharmacol, 73(4), 839-45.
  11. del Giglio A, Soares HP, Caparroz C, Castro PC (2000). Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer, 89(11), 2301-8.
  12. Kim R, Sanoff H, Poklepovic A, Soares H, Kim J, Lyu J, Liu Y, Kim D (2020). A multi-institutional phase II trial of regorafenib in refractory advanced biliary tract cancer. Accepted. Cancer.
  13. Soares HP, Kumar A, Djulbegovic B (2007). Evidence profiles for breast cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 33(1), 87-9.
  14. Soares HP, Kumar A, Djulbegovic B (2006). Evidence profiles for lung cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 32(8), 652-5.
  15. Kumar A, Soares HP, Djulbegovic B (2006). Evidence profiles for colo-rectal cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 32(7), 577-80.
  16. Djulbegovic B, Soares HP, Kumar A (2006). What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms. Cancer Treat Rev, 32(7), 572-6.
  17. Kumar A, Soares HP (2006). Salvage radiotherapy increases survival in people with residual disease after chemotherapy for advance diffuse large cell lymphoma. Cancer Treat Rev, 32(6), 487-90.
  18. Mahipal A, Tella SH, Kommalapati A, Goyal G, Soares H, Neuger A, Copolla D, Kim J, Kim R (2019). Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Invest New Drugs, 37(3), 473-481.
  19. Cives M, Anaya DA, Soares H, Coppola D, Strosberg J (2018). Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors. J Natl Cancer Inst, 110(3), 282-289.
  20. Mhaskar R, Djulbegovic B, Magazin A, Soares HP, Kumar (2012). Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. Journal of clinical epidemiology, 65(6), 602-9.
  21. Djulbegovic B, Kumar A, Magazin A, Schroen AT, Soares H, Hozo I, Clarke M, Sargent D, Schell M (2011). Optimism bias leads to inconclusive results-an empirical study. Journal of clinical epidemiology, 64(6), 583-93.
  22. Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J, Maithel S (2019). Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. Journal of clinical oncology, 37(12), 1015-1027.
  23. Kumar A, Soares HP, Balducci L, Djulbegovic B, National Cancer Institute (2007). Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. Journal of clinical oncology, 25(10), 1272-6.
  24. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields A (2008). Recommendations on the use of 18F-FDG PET in oncology. Journal of nuclear medicine, 49(3), 480-508.
  25. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, STOPIT-2 Study Group., Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schünemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay (2010). Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA, 303(12), 1180-7.
  26. Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic (2005). Evaluation of new treatments in radiation oncology: are they better than standard treatments?. JAMA, 293(8), 970-8.
  27. Eads JR, Reidy-Lagunes D, Soares HP, Chan JA, Anthony LB, Halfdanarson TR, Naraev BG, Wolin EM, Halperin DM, Li D, Pommier RF, Zacks JS, Morse MA, Metz DC, from the Carcinoid Syndrome Control Collaborative (2020). Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. Pancreas, 49(9), 1123-1130.
  28. Trufelli DC, Bensi CG, Garcia JB, Narahara JL, Abrão MN, Diniz RW, Miranda Vda C, Soares HP, Del Giglio (2008). Burnout in cancer professionals: a systematic review and meta-analysis. European journal of cancer care, 17(6), 524-31.
  29. Kumar A, Soares H, Serdarevic (2005). Totality of evidence: one of the keys to better oncology management. The Journal of oncology management, 14(1), 12-4.
  30. Samano ES, Goldenstein PT, Ribeiro Lde M, Lewin F, Filho ES, Soares HP, del Giglio (2004). Praying correlates with higher quality of life: results from a survey on complementary/alternative medicine use among a group of Brazilian cancer patients. Sao Paulo medical journal = Revista paulista de medicina, 122(2), 60-3.
  31. Rocha-Lima CM, Soares HP, Raez LE, Singal (2007). EGFR targeting of solid tumors. Cancer control, 14(3), 295-304.
  32. Behera M, Kumar A, Soares HP, Sokol L, Djulbegovic (2007). Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer control, 14(2), 160-6.
  33. Djulbegovic B, Kumar A, Glasziou PP, Perera R, Reljic T, Dent L, Raftery J, Johansen M, Di Tanna GL, Miladinovic B, Soares HP, Vist GE, Chalmers (2012). New treatments compared to established treatments in randomized trials. The Cochrane database of systematic reviews, 10, MR000024.
  34. Soares HP, Lutzky (2010). Velimogene aliplasmid. Expert opinion on biological therapy, 10(5), 841-51.
  35. Fonseca FL, Soares HP, Manhani AR, Bendit I, Novaes M, Zatta SM, Arias V, Pinhal MA, Weinschenker P, del Giglio (2002). Peripheral blood c-erbB-2 expression by reverse transcriptase-polymerase chain reaction in breast cancer patients receiving chemotherapy. Clinical breast cancer, 3(3), 201-5.
  36. Soares HP, Ming M, Mellon M, Young SH, Han L, Sinnet-Smith J, Rozengurt (2015). Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Molecular cancer therapeutics, 14(4), 1014-23.
  37. Rozengurt E, Soares HP, Sinnet-Smith (2014). Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Molecular cancer therapeutics, 13(11), 2477-88.
  38. Mosley SA, Hicks JK, Portman DG, Donovan KA, Gopalan P, Schmit J, Starr J, Silver N, Gong Y, Langaee T, Clare-Salzler M, Starostik P, Chang YD, Rajasekhara S, Smith JE, Soares HP, George TJ Jr, McLeod HL, Cavallari L (2018). Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial. Contemporary clinical trials, 68, 7-13.
  39. Briel M, Lane M, Montori VM, Bassler D, Glasziou P, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Culebro CR, da Silva SA, Flynn DN, Elamin MB, Strahm B, Murad MH, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Abu Elnour NO, You JJ, Karanicolas PJ, Bucher HC, Lampropulos JF, Nordmann AJ, Burns KE, Mulla SM, Raatz H, Sood A, Kaur J, Bankhead CR, Mullan RJ, Nerenberg KA, Vandvik PO, Coto-Yglesias F, Schünemann H, Tuche F, Chrispim PP, Cook DJ, Lutz K, Ribic CM, Vale N, Erwin PJ, Perera R, Zhou Q, Heels-Ansdell D, Ramsay T, Walter SD, Guyatt G (2009). Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). Trials, 10, 49.
  40. Ming M, Sinnett-Smith J, Wang J, Soares HP, Young SH, Eibl G, Rozengurt (2014). Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. PloS one, 9(12), e114573.
  41. Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt (2013). Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PloS one, 8(2), e57289.
  42. Tanvetyanon T, Soares HP, Djulbegovic B, Jacobsen PB, Bepler (2007). A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. Journal of thoracic oncology, 2(12), 1091-7.
  43. Wainberg ZA, Alsina M, Soares HP, Braña I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, Pathan N, Pierce KJ, Siu LL, Vermette J, Tabernero (2017). A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Targeted oncology, 12(6), 775-785.
  44. Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares H (2019). Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. Journal of gastrointestinal oncology, 10(4), 647-687.
  45. Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler (2021). Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 19(7), 839-868.
  46. Al-Toubah T, Schell MJ, Cives M, Zhou JM, Soares HP, Strosberg J (2020). A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. Neuroendocrinology, 110(5), 377-383.
  47. Florou V, Elliott A, Bailey MH, Stone D, Affolter K, Soares HP, Nevala-Plagemann C, Scaife C, Walker P, Korn WM, Lou E, Shroff RT, Hosein PJ, Garrido-Laguna (2023). Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clinical cancer research, 29(17), 3408-3417.
  48. Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan J (2023). Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocrine-related cancer, 30(8),
  49. Leiter RE, Varas MTB, Miralda K, Muneton-Castano Y, Furtado G, Revette A, Cronin C, Soares HP, Lopez A, Hayman LL, Lindsay AC, Schrag D, Enzinger A (2023). Adaptation of a Multimedia Chemotherapy Educational Intervention for Latinos: Letting Patient Narratives Speak for Themselves. Journal of cancer education, 38(4), 1353-1362.
  50. Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, Soares HP, Puri S, Swami U, Wilky B, Hosein P, Trent J, Lopes GL, Park W, Garrido-Laguna (2023). Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. Journal for immunotherapy of cancer, 11(8),
  51. Okwundu N, Weil CR, Soares HP, Fine GC, Cannon D (2023). Case report: Efficacy of lutetium-177 oxodotreotide for neuroendocrine tumor with central nervous system metastases. Frontiers in nuclear medicine, 3, 1074948.
  52. Sahai V, Griffith KA, Lin BS, Soares HP, Chandana SR, Crysler O, Kumar-Sinha C, Enzler T, Dippman D, Gunchick V, Zalupski M (2024). BilT03: Phase 1b/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer. Med (New York, N.Y.), 100547.
  53. Norton C, Shaw MS, Rubnitz Z, Smith J, Soares HP, Nevala-Plagemann CD, Garrido-Laguna I, Florou (2025). KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. JAMA network open, 8(1), e2453588.
  54. Mosley SA, Cicali E, Del Cueto A, Portman DG, Donovan KA, Gong Y, Langaee T, Gopalan P, Schmit J, Starr JS, Silver N, Chang YD, Rajasekhara S, Smith JE, Soares HP, Clare-Salzler M, Starostik P, George TJ, McLeod HL, Fillingim RB, Hicks JK, Cavallari L (2023). CYP2D6-guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial. Pharmacotherapy, 43(12), 1286-1296.
  55. Xue E, Bracken-Clarke D, Krause H, Adeyelu T, Evans MG, Akbulut D, Quezado M, Gandhi N, Farrell A, Soares HP, Lou E, Phan M, Patel R, Vanderwalde AM, Elliott A, Steuer CE, Saba NF, Lubin DJ, London NR Jr, Gulley JL, Floudas C (2024). Characterization of Somatostatin Receptor 2 Gene Expression and Immune Landscape in Sinonasal Malignancies. Cancers, 16(23),
  56. Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, Kelkar AH, Law LY, LeFebvre KB, Ljungman P, Miller ED, Meyer LA, Moore HN, Soares HP, Taplitz RA, Woldetsadik ES, Kohn E (2024). Vaccination of Adults With Cancer: ASCO Guideline. Journal of clinical oncology, 42(14), 1699-1721.
  57. Wilbur HC, Soares HP, Azad N (2024). Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations. Hepatology (Baltimore, Md.),
  58. O'Rorke M, Chrischilles E, NET'PRO Study Investigator (2024). Making progress against rare cancers: A case study on neuroendocrine tumors. Cancer, 130(9), 1568-1574.
  59. Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland E (2023). Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. Journal of clinical oncology, 41(32), 5049-5067.
  60. Marsiglio J, McPherson JP, Kovacsovics-Bankowski M, Jeter J, Vaklavas C, Swami U, Grossmann D, Erickson-Wayman A, Soares HP, Kerrigan K, Gibson B, Doherty JA, Hyngstrom J, Hardikar S, Hu-Lieskovan (2023). A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome. Frontiers in immunology, 14, 1229823.
  61. Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL, NET CTPM participant (2023). Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. Journal of the National Cancer Institute, 115(9), 1001-1010.
  62. Lozada JR, Elliott A, Evans MG, Wacker J, Storey KM, Egusa EA, Zorko NA, Kumar A, Crymes A, Heath EI, Carneiro BA, Soares HP, Cichocki F, Miller JS, Lou E, Beltran H, Antonarakis ES, Ryan CJ, Hwang J (2025). Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting. Cancer research communications, 5(2), 318-326.
  63. Parsons M, Lloyd S, Johnson S, Scaife C, Soares H, Kim R, Kim R, Garrido-Laguna I, Tao (2023). The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. Journal of gastrointestinal cancer, 54(2), 492-500.
  64. Perez K, Del Rivero J, Kennedy EB, Basu S, Chauhan A, Connolly HM, Dasari AN, Gangi A, Clarke CN, Hallet J, Howe JR, Grady E, Ivanidze J, Mittra ES, White SB, Raj NP, Vijayvergia N, Lewis MA, Chan JA, Kunz PL, Mailman J, Arshad J, Soares HP, Singh S, Chandrasekharan C, Soulen MC, Janson ET, Halfdanarson TR, Strosberg JR, Bergsland E (2025). Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. JCO oncology practice, OP2500133.
  65. Azar I, Khan HY, Bannoura SF, Gandhi N, Uddin MH, Nagasaka M, Gong J, Nazha B, Choucair K, Vojjala N, Khushman MM, Soares HP, El-Deiry WS, Philip PA, El-Rayes B, Chen H, Lou E, Muqbil I, Farrell AP, Swensen J, Oberley MJ, Nabhan C, Goel S, Shields AF, Mohammad RM, Pasche BC, Azmi A (2025). Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations. JCO oncology advances, 2(1), e2400032.
  66. Su DG, Brown LM, Bansal VV, Bakkila B, Concors SJ, Turaga KK, Gunderson C, Bergsland E, Strosberg JR, Halfdanarson TR, Metz DC, Kunstman JW, Kunz PL, Gangi A, Peritoneal Surface Malignancies (PSM) Consortium Grou (2025). Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms. Annals of surgical oncology,
  67. Su DG, Brown LM, Bansal VV, Bakkila B, Concors SJ, Turaga KK, Gunderson C, Bergsland E, Strosberg JR, Halfdanarson TR, Metz DC, Kunstman JW, Kunz PL, Gangi A, Peritoneal Surface Malignancies Consortium Grou (2025). Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms. Cancer, 131(13), e35871.
  68. Sukrithan V, Ahmed U, Krause H, Gandhi N, Elliott A, Hinton A, Walker P, Vanderwalde A, Zhou Y, Patel DC, Lou E, Soares HP, Rogers KA, Konda (2025). Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms. Endocrine-related cancer, 32(7),
  69. Wheless MC, Stockton S, Soares HP, Dayyani F, Saeed A, Kim E, Jin N, Yacoub G, Florou V, Ayers GD, Guerrouahen BS, Contreras A, Li L, Ferry-Galow KV, Gore S, Das S, Berlin (2025). NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer. The oncologist, 30(12),
  70. Marks JA, Sweeney K, Elliott A, Gupta B, VanderWalde A, Puri S, Shields MD, Nieva JJ, Soares HP, Ma PC, Halmos B, Liu S (2026). SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 213, 108913.
  71. O'Rorke MA, Gryzlak BM, Xu T, McDowell BD, DeCook RR, Rudzianski NJ, Serrano KC, Wehrheim AM, Grewal US, Chandrasekharan C, Dillon JS, Halfdanarson TR, Schnell MJ, Witter CL, Gamblin TC, Kazmi S, Cowell LG, Else T, Soares HP, Sukrithan V, Chandaka S, Sanoff HK, He FC, Geller DA, Ramirez RA, Liu M, Lancaster W, Mailman JA, Moran H, Wahmann M, Gellerman E, Chrischilles E (2026). Using a participation monitoring database to enhance recruitment in a rare cancer population. Journal of clinical and translational science, 10(1), e40.
  72. O'Rorke MA, Xu T, Decook RR, Mcdowell BD, Gryzlak BM, Rudzianski NJ, Serrano KC, Wehrheim AM, Grewal US, Chandrasekharan C, Dillon JS, Halfdanarson TR, Gamblin TC, Cowell LG, Else T, Soares HP, Sukrithan V, Chandaka S, Sanoff HK, He FC, Geller D, Ramirez RA, Liu M, Lancaster W, Mailman JA, Moran H, Wahmann M, Gellerman E, Chrischilles EA, NET-PRO Study Investigator (2026). Quality of life and care experiences in a US multi-institutional neuroendocrine tumor cohort. Journal of the National Cancer Institute,

Review

  1. Jacob A, Raj R, Allison DB, Soares HP, Chauhan (2022). An Update on the Management of Mixed Neuroendocrine-Non-neuroendocrine Neoplasms (MiNEN). Current treatment options in oncology, 23(5), 721-735.
  2. Egal ESA, Jacenik D, Soares HP, Beswick E (2021). Translational challenges in pancreatic neuroendocrine tumor immunotherapy. Biochimica et biophysica acta. Reviews on cancer, 1876(2), 188640.
  3. Hunter LA, Soares H (2021). Quality of Life and Symptom Management in Advanced Biliary Tract Cancers. Cancers, 13(20),
  4. Chauhan A, Del Rivero J, Ramirez RA, Soares HP, Li (2022). Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review. Cancers, 14(21),
  5. Naraev BG, Mailman J, Halfdanarson TR, Soares HP, Mittra ES, Hallet (2023). Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors. Expert review of anticancer therapy, 23(6), 601-615.
  6. Scarini JF, Gonçalves MWA, de Lima-Souza RA, Lavareze L, de Carvalho Kimura T, Yang CC, Altemani A, Mariano FV, Soares HP, Fillmore GC, Egal ES (2024). Potential role of the Eph/ephrin system in colorectal cancer: emerging druggable molecular targets. Frontiers in oncology, 14, 1275330.
  7. Nemunaitis JM, Brown-Glabeman U, Soares H, Belmonte J, Liem B, Nir I, Phuoc V, Gullapalli R (2018). Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico. BMC cancer, 18(1), 665.
  8. El-Haddad G, Gardner L, Kim H, Soares H (2026). Occurrence and Management of Acute, Subacute, and Delayed Toxicities in Patients with GEP-NETs Following Treatment with Radioligand Therapy. Cancers, 18(5),

Book Chapter

  1. Soares HP, Strosberg (2016). Targeted Therapies for Neuroendocrine Neoplasms.
  2. Soares HP, Kumar A, Bennett C, Djulbegovic (2008). The Role of Hematopoietic Growth Factors in Managing Patients with Hematologic Malignancies. 402-12.

Editorial

  1. Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe J (2020). North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas, 49(6), 723-728.

Letter

  1. Ryan CE, Saif A, Rocha F, Philip P, Hernandez JM, Ahmad S, Soares (2023). Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors. Annals of surgical oncology, 30(3), 1302-1304.

Other

  1. Loaiza-Bonilla A, Benson AB 3rd, Grothey A, Karimi M, Klempner SJ, Lin D, Mahtani R, Soares H (2021). Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. The oncologist, 26(8), 651-659.